News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,298 Results
Type
Article (41527)
Company Profile (293)
Press Release (656478)
Section
Business (209769)
Career Advice (2062)
Deals (36553)
Drug Delivery (89)
Drug Development (82602)
Employer Resources (171)
FDA (16399)
Job Trends (15331)
News (354506)
Policy (33783)
Tag
Academia (2572)
Africa (775)
Alliances (50963)
Alzheimer's disease (1159)
Approvals (16318)
Arizona (181)
Artificial intelligence (79)
Asia (39657)
Australia (6319)
Bankruptcy (360)
Best Places to Work (11406)
Biosimilars (67)
Biotechnology (191)
C2C Services and Suppliers (79714)
California (1849)
Canada (923)
Cancer (482)
Career advice (1724)
Cell therapy (120)
China (148)
Clinical research (64702)
Collaboration (135)
Colorado (75)
Compensation (80)
Connecticut (74)
COVID-19 (2556)
Cystic fibrosis (74)
Data (291)
Diabetes (81)
Diagnostics (6049)
Drug pricing (70)
Earnings (85317)
Employer resources (146)
Europe (84198)
Events (110605)
Executive appointments (152)
FDA (16612)
Florida (261)
Funding (145)
Gene therapy (99)
GLP-1 (539)
Government (4407)
Healthcare (18788)
Hotbed/Location (489719)
Illinois (258)
Indiana (152)
Infectious disease (2583)
Inflammatory bowel disease (94)
Interviews (317)
IPO (16471)
Job creations (4045)
Job search strategy (1483)
Kansas (94)
Layoffs (414)
Legal (8290)
Lung cancer (110)
Manufacturing (90)
Maryland (391)
Massachusetts (1534)
Medical device (13122)
Medtech (13127)
Mergers & acquisitions (19932)
Metabolic disorders (256)
Michigan (124)
Minnesota (214)
Neuroscience (1306)
New Jersey (581)
New York (583)
NextGen Class of 2024 (6605)
Non-profit (4503)
North Carolina (597)
Northern California (817)
Obesity (152)
Ohio (104)
Opinion (194)
Patents (70)
Pennsylvania (575)
People (57779)
Pharmaceutical (85)
Phase I (19960)
Phase II (28467)
Phase III (21406)
Pipeline (108)
Postmarket research (2636)
Preclinical (8490)
Press Release (68)
Rare diseases (133)
Real estate (6229)
Recruiting (66)
Regulatory (22009)
Research institute (2354)
Resumes & cover letters (355)
South America (1153)
Southern California (748)
Startups (3708)
Texas (240)
United States (8529)
Vaccines (487)
Washington State (253)
Weight loss (137)
Date
Today (113)
Last 7 days (694)
Last 30 days (2372)
Last 365 days (37850)
2024 (26380)
2023 (40629)
2022 (51798)
2021 (56333)
2020 (54797)
2019 (47401)
2018 (35773)
2017 (33141)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28497)
698,298 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.
September 11, 2024
·
1 min read
·
Heather McKenzie
Layoffs
BioMarin to Lay Off 225 Employees Globally
Last week, BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.
August 29, 2024
·
1 min read
·
Angela Gabriel
C-suite
BioMarin Brings on Roche, Amgen Alums in Executive Restructuring
As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.
August 22, 2024
·
2 min read
·
Tristan Manalac
Gene therapy
BioMarin Narrows Roctavian Efforts to U.S., Germany, Italy as Sales Stagnate
BioMarin Pharmaceuticals on Monday said it is restricting sales of its hemophilia A gene therapy to three countries in an effort to reduce costs and help the treatment become profitable by 2025.
August 6, 2024
·
2 min read
·
Tristan Manalac
Business
BioMarin Rolls Out $4B Revenue Expectations, as Analysts Wonder About Pipeline
BioMarin executives sought to calm an anxious investor base Wednesday with a public address and pledge to achieve a nearly 50% bump in annual revenue by 2027. But analysts were left wanting.
September 5, 2024
·
7 min read
·
Annalee Armstrong
Business
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
April 24, 2024
·
24 min read
Biotech Bay
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
BioMarin Pharmaceutical Inc. will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.
June 7, 2024
·
15 min read
Biotech Bay
BioMarin Scheduled to Participate in March Investor Conferences
BioMarin Pharmaceutical Inc. today announced management is scheduled to participate in four upcoming investor conferences in March.
March 1, 2024
·
2 min read
Drug Development
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children’s Bone Health
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length while maintaining bone strength.
June 17, 2024
·
13 min read
Biotech Bay
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin Pharmaceutical Inc. announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.
May 8, 2024
·
1 min read
1 of 69,830
Next
